HC Wainwright Issues Positive Forecast for Sensus Healthcare (NASDAQ:SRTS) Stock Price

Sensus Healthcare (NASDAQ:SRTS) had its price target increased by research analysts at HC Wainwright from $11.00 to $12.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 105.48% from the company’s previous close.

A number of other equities research analysts have also recently commented on SRTS. Maxim Group lifted their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Lake Street Capital assumed coverage on Sensus Healthcare in a research note on Friday, January 31st. They issued a “buy” rating and a $18.00 target price on the stock.

Sensus Healthcare Price Performance

Shares of NASDAQ:SRTS opened at $5.84 on Monday. Sensus Healthcare has a 1 year low of $2.91 and a 1 year high of $9.33. The company has a market capitalization of $95.72 million, a PE ratio of 14.60 and a beta of 1.24. The business has a fifty day moving average price of $7.38 and a two-hundred day moving average price of $6.88.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. Sell-side analysts anticipate that Sensus Healthcare will post 0.71 earnings per share for the current year.

Institutional Trading of Sensus Healthcare

Institutional investors have recently modified their holdings of the business. Truvestments Capital LLC bought a new stake in Sensus Healthcare during the 3rd quarter valued at $32,000. IFP Advisors Inc purchased a new position in shares of Sensus Healthcare in the fourth quarter valued at $95,000. Cubist Systematic Strategies LLC bought a new stake in shares of Sensus Healthcare during the 2nd quarter valued at $156,000. XTX Topco Ltd lifted its holdings in Sensus Healthcare by 76.0% during the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after purchasing an additional 13,619 shares in the last quarter. Finally, Sigma Planning Corp bought a new position in Sensus Healthcare in the 4th quarter worth about $215,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.